Basking Biosciences commissioned Axxiem to help them come out of stealth mode with a new website that tells their unique story, with a specific focus on speaking to the investor market. The resulting website is a captivating design with smart use of text and graphics in a visually appealing and user-friendly design that clearly communicates the company's novel therapy and how it can revolutionize acute thrombosis treatment.
Basking Biosciences is focused on improving the treatment of acute thrombosis, with acute ischemic stroke being its lead clinical indication. Basking’s first-in-class reversible RNA aptamer, BB-031, is designed to be safer, more effective, and greatly expand the population receiving acute revascularization therapy.
After learning more about the company, Axxiem developed customized infographics, a pipeline, and MOA graphics to clearly show the company's therapy and potential impact.
Graphics
